Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

It is generally accepted that recent advances in anticancer agents have contributed
significantly to the improvement of both the disease-free survival and quality of life in cancer …

Background: Clinical response to chemotherapy for ovarian cancer is frequently
compromised by the development of drug-resistant disease. The underlying molecular …

The development of drug resistance continues to be a dominant hindrance toward curative
cancer treatment. Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and …

Epithelial ovarian cancers (EOCs) have conventionally been treated with cytoreductive
surgery followed by platinum-and taxane-based chemotherapy. Each of the EOC histotypes …

Many cancer therapeutic agents elicit resistance that renders them ineffective and often
produces cross-resistance to other drugs. One of the most common mechanisms of …

Simple Summary Overexpression of ABCB1 has been identified in a wide range of multidrug-
resistant cancers. ABCB1 can become upregulated in many ways, and understanding these …

Paclitaxel is commonly used to treat breast, ovarian, lung, esophageal, gastric, pancreatic
cancer, and neck cancer cells. Cancer recurrence is observed in patients treated with …

The design, synthesis, and biological evaluation of a new family of highly effective cell-
penetrating molecular transporters, guanidinium-rich oligophosphoesters, are described …

Multidrug resistance (MDR) remains a major obstacle to effective chemotherapy treatment in
ovarian cancer. In our study, paclitaxel-resistant ovarian cancer patients and cell lines had …